The end of a shortage of popular weight-loss drugs may mean many people lose access to them

The FDA updated its database of drugs in shortage to remove tirzepatide, which had sat on that list – along with related semaglutide-based drugs, Ozempic and Wegovy – since 2022 amid unprecedented demand.